RU2010113977A - Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae - Google Patents

Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae Download PDF

Info

Publication number
RU2010113977A
RU2010113977A RU2010113977/15A RU2010113977A RU2010113977A RU 2010113977 A RU2010113977 A RU 2010113977A RU 2010113977/15 A RU2010113977/15 A RU 2010113977/15A RU 2010113977 A RU2010113977 A RU 2010113977A RU 2010113977 A RU2010113977 A RU 2010113977A
Authority
RU
Russia
Prior art keywords
diseases
disease
asp
peptide
cys
Prior art date
Application number
RU2010113977/15A
Other languages
English (en)
Inventor
Дориан БЕВЕК (DE)
Дориан БЕВЕК
Фабио КАВАЛЛИ (CH)
Фабио КАВАЛЛИ
Вера КАВАЛЛИ (CH)
Вера КАВАЛЛИ
Геральд БАХЕР (DE)
Геральд БАХЕР
Original Assignee
Мондобайотек Лабораториз Аг (Li)
Мондобайотек Лабораториз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мондобайотек Лабораториз Аг (Li), Мондобайотек Лабораториз Аг filed Critical Мондобайотек Лабораториз Аг (Li)
Publication of RU2010113977A publication Critical patent/RU2010113977A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

1. Сочетание пептидов Ac-Pen-Arg-Gly-Asp-Cys-OH и Thr-Asp-Thr-Ser-His-His-Asp-Gln-Asp-His-Pro-Thr-Phe-Asn-OH или их солей, гидратов или деацетилированной формы. ! 2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%. ! 3. Сочетание по п.1 для применения в медицине. !4. Применение пептида Ac-Pen-Arg-Gly-Asp-Cys-OH или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны инфекции Streptococus pneumoniae, связанных с инфекцией Streptococus pneumoniae заболеваний, а именно гемолитического уремического синдрома, пневмонии, менингита, осложнения кистозного фиброза, заболеваний среднего уха, инфекций в кровотоке, инфекции синусов и ушей, острого синусита, отита среднего уха, остеомиелита, септического артрита, эндокардита, перитонита, перикардита и абсцесса головного мозга. ! 6. Применение пептида Ac-Pen-Arg-Gly-Asp-Cys-OH для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 7. Применение пептида Ac-Pen-Arg-Gly-Asp-Cys-OH для получения лиофилизированного состава или буферного жидкого состава. ! 8. Фармацевтическая композиция, содержащая сочетание по п.1 по меньше

Claims (12)

1. Сочетание пептидов Ac-Pen-Arg-Gly-Asp-Cys-OH и Thr-Asp-Thr-Ser-His-His-Asp-Gln-Asp-His-Pro-Thr-Phe-Asn-OH или их солей, гидратов или деацетилированной формы.
2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%.
3. Сочетание по п.1 для применения в медицине.
4. Применение пептида Ac-Pen-Arg-Gly-Asp-Cys-OH или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны инфекции Streptococus pneumoniae, связанных с инфекцией Streptococus pneumoniae заболеваний, а именно гемолитического уремического синдрома, пневмонии, менингита, осложнения кистозного фиброза, заболеваний среднего уха, инфекций в кровотоке, инфекции синусов и ушей, острого синусита, отита среднего уха, остеомиелита, септического артрита, эндокардита, перитонита, перикардита и абсцесса головного мозга.
6. Применение пептида Ac-Pen-Arg-Gly-Asp-Cys-OH для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
7. Применение пептида Ac-Pen-Arg-Gly-Asp-Cys-OH для получения лиофилизированного состава или буферного жидкого состава.
8. Фармацевтическая композиция, содержащая сочетание по п.1 по меньшей мере совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
9. Фармацевтическая композиция по п.8 в форме лиофилизата или жидкого буферного раствора.
10. Фармацевтическая композиция по п.8 или 9, подходящая для внутривенного введения, перорального введения или для введения посредством ингаляции.
11. Фармацевтическая композиция по п.8 или 9 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
12. Фармацевтическая композиция по п.8 или 9, подходящая для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезни обмена веществ.
RU2010113977/15A 2007-09-11 2008-09-09 Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae RU2010113977A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07017748.0 2007-09-11
EP07017748 2007-09-11

Publications (1)

Publication Number Publication Date
RU2010113977A true RU2010113977A (ru) 2011-10-20

Family

ID=40225088

Family Applications (8)

Application Number Title Priority Date Filing Date
RU2010113981/15A RU2010113981A (ru) 2007-09-11 2008-09-09 Применение гексапептидного антагониста рецептора тромбоцитарного фибриногена и альфа-эндорфина в качестве терапевтических средств
RU2010114027/15A RU2010114027A (ru) 2007-09-11 2008-09-09 Большой гастрин i в качестве терапевтического средства
RU2010114025/15A RU2010114025A (ru) 2007-09-11 2008-09-09 ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010114047/15A RU2010114047A (ru) 2007-09-11 2008-09-09 Применение нейропептида af человека в качестве терапевтического средства
RU2010113977/15A RU2010113977A (ru) 2007-09-11 2008-09-09 Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
RU2010113995/15A RU2010113995A (ru) 2007-09-11 2008-09-09 Применение ацетил-(ala10,11)-rantes(1-14) и/или кальцитонина в качестве антиангиогенных средств
RU2010114000/15A RU2010114000A (ru) 2007-09-11 2008-09-09 Применение нейропептида sf индивидуально или в сочетании с glp-2 в качестве терапевтического средства
RU2010113966/15A RU2010113966A (ru) 2007-09-11 2008-09-09 Применение меланотропинстимулирующего фактора в качестве терапевтического средства

Family Applications Before (4)

Application Number Title Priority Date Filing Date
RU2010113981/15A RU2010113981A (ru) 2007-09-11 2008-09-09 Применение гексапептидного антагониста рецептора тромбоцитарного фибриногена и альфа-эндорфина в качестве терапевтических средств
RU2010114027/15A RU2010114027A (ru) 2007-09-11 2008-09-09 Большой гастрин i в качестве терапевтического средства
RU2010114025/15A RU2010114025A (ru) 2007-09-11 2008-09-09 ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010114047/15A RU2010114047A (ru) 2007-09-11 2008-09-09 Применение нейропептида af человека в качестве терапевтического средства

Family Applications After (3)

Application Number Title Priority Date Filing Date
RU2010113995/15A RU2010113995A (ru) 2007-09-11 2008-09-09 Применение ацетил-(ala10,11)-rantes(1-14) и/или кальцитонина в качестве антиангиогенных средств
RU2010114000/15A RU2010114000A (ru) 2007-09-11 2008-09-09 Применение нейропептида sf индивидуально или в сочетании с glp-2 в качестве терапевтического средства
RU2010113966/15A RU2010113966A (ru) 2007-09-11 2008-09-09 Применение меланотропинстимулирующего фактора в качестве терапевтического средства

Country Status (8)

Country Link
US (8) US20100210532A1 (ru)
EP (8) EP2187908A1 (ru)
JP (8) JP2010539023A (ru)
KR (8) KR20100058549A (ru)
AU (8) AU2008297899A1 (ru)
CA (8) CA2698775A1 (ru)
RU (8) RU2010113981A (ru)
WO (20) WO2009033659A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2259768B1 (en) 2008-04-08 2019-05-22 Merck Patent GmbH Compositions containing cyclic peptides and methods of use
EP2509583B1 (en) * 2009-12-10 2019-05-15 Merck Patent GmbH Pharmaceutical composition comprising oligopeptides, preferably cilengitide
US8835470B2 (en) * 2010-04-23 2014-09-16 Bristol-Myers Squibb Company Mandelamide heterocyclic compounds
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
ES2720477T3 (es) * 2011-06-09 2019-07-22 Merck Patent Gmbh Tratamiento de cánceres y metástasis con suspensiones de Cilengitide en portador
US9988422B2 (en) 2011-09-29 2018-06-05 Stealth Biotherapeutics Corp Aromatic-cationic peptides and methods for using same
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
US9670259B2 (en) * 2013-03-14 2017-06-06 University Of Rochester Method of inhibiting angiogenesis using inhibitors of G-protein-coupled receptor kinase interacting protein-1 (GIT1)
EP2941091B1 (en) 2014-04-30 2019-04-24 Electrolux Appliances Aktiebolag Hob with free configurable heating array and touchscreen control, method for operating a hob with free configurable heating array and touchscreen control and computer program product
RU2577135C2 (ru) * 2014-07-01 2016-03-10 Диамондзлите Лимитед Способ лечения пациентов с онкологическими заболеваниями кожи при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный, плоскоклеточный рак (варианты)
CN104888198A (zh) * 2015-04-21 2015-09-09 徐志强 降钙素在制造延缓脑老化药物的新用途
WO2017019496A1 (en) * 2015-07-24 2017-02-02 Berenson James Richard Gamma secretase modulators for the treatment of immune system dysfunction
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
CN108395470B (zh) * 2018-01-10 2020-10-09 北京工业大学 具有抑制登革病毒复制作用的短肽及其应用
JP6709440B2 (ja) * 2018-06-08 2020-06-17 学校法人福岡大学 肥厚性瘢痕の形成抑制用組成物
CN111647043B (zh) * 2019-08-07 2022-03-22 中国农业大学 含有Hyp-Gly序列的一类抗血小板和抗血栓功能的寡肽
CA3235242A1 (en) * 2021-10-25 2023-05-04 Christian Lutken Modified tripeptides for use in the treatment of a non-enveloped virus infection

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097471A (en) * 1977-05-26 1978-06-27 American Home Products Corporation Polypeptides with morphine-like activity
EP0076676B1 (en) * 1981-10-05 1986-12-30 Tni Pharmaceuticals, Inc. Process for using endorphins as antitumour agents
JPS6023086B2 (ja) * 1982-09-04 1985-06-05 工業技術院長 アンジオテンシン転換酵素阻害剤
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474753A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
JPS62270533A (ja) * 1986-05-20 1987-11-24 Agency Of Ind Science & Technol 経口摂食物
CA1324954C (en) * 1988-03-10 1993-12-07 Erkki I. Ruoslahti Inhibition of cell migration with synthetic peptides
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
CA2008534A1 (en) * 1989-01-26 1990-07-26 Donald E. Ingber Method for inhibiting tumor recurrence after surgical resection
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5256396A (en) 1990-01-24 1993-10-26 Colgate-Palmolive Company Topical composition
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
JP2745351B2 (ja) * 1991-02-14 1998-04-28 富士写真フイルム株式会社 ペプチド誘導体及びその用途
DE69128283T2 (de) 1991-08-12 1998-03-19 Nestle Sa Nahrungsmittelzusammensetzung
WO1993008818A1 (en) * 1991-11-07 1993-05-13 The University Of Southern California Compositions and methods for preventing adhesion formation
JP2918746B2 (ja) * 1991-12-18 1999-07-12 富士写真フイルム株式会社 ペプチド誘導体およびその用途
MX9301789A (es) * 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
US5817628A (en) * 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
WO1994017097A1 (en) * 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
CA2172493C (en) * 1993-09-24 2003-09-16 Kathleen Elizabeth Rodgers Use of angiotensin iii and analogs thereof in tissue repair
JP3581174B2 (ja) * 1993-09-30 2004-10-27 新日本製鐵株式会社 新規ペプチド並びにそれを用いた血小板凝集抑制剤、体外循環用血液凝固抑制剤及び輸血用血小板製剤保護剤
US5721213A (en) * 1993-09-30 1998-02-24 Nippon Steel Corporation Peptides, active as inhibitors of platelet aggregation
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
CZ292360B6 (cs) 1994-05-06 2003-09-17 Pfizer Inc. Dávkovací forma s řízeným uvolňováním obsahující azithromycin a způsob její výroby
DE19529909C2 (de) * 1995-08-15 1998-04-09 Fresenius Ag Wässrige Spüllösung
US5691314A (en) * 1996-03-18 1997-11-25 The Medical College Of Hampton Roads Adjunctive therapy
AU3499997A (en) * 1996-06-24 1998-01-14 Rockefeller University, The Method of using ligands of the kappa opioid receptor
TW360501B (en) 1996-06-27 1999-06-11 Nestle Sa Dietetically balanced milk product
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
ES2148670T3 (es) 1996-09-24 2000-10-16 Nestle Sa Sustituto de la leche y procedimiento de fabricacion.
GB9704174D0 (en) * 1997-02-28 1997-04-16 Univ Birmingham Agent for medical treatment
WO1999003491A1 (en) * 1997-07-15 1999-01-28 Novo Nordisk A/S New use of nociceptin
IT1299134B1 (it) * 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
WO1999040106A2 (en) * 1998-02-09 1999-08-12 University Of Southern California Use of angiotensin analogues for promoting erythropoiesis
US5958874A (en) * 1998-02-18 1999-09-28 The Research Foundation Of State University Of New York Recombinant fibronectin-based extracellular matrix for wound healing
ATE271783T1 (de) 1998-11-24 2004-08-15 Nestle Sa Verfahren zur herstellung einer proteinzusammenzetzung und einer diese enthaltenden säuglingsnahrung
WO2001017958A2 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Neuropeptide sf receptor assays, compounds and therapeutic methods
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
PT1392348E (pt) * 2001-04-30 2008-09-09 Aeterna Zentaris Gmbh Tratamento de demência e doenças neurodegenerativas com doses intermédias de antagonistas de lhrh
US8633150B2 (en) * 2001-05-16 2014-01-21 Tni Biotech, Inc. Methods for inducing sustained immune response
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
ATE362707T1 (de) 2001-11-23 2007-06-15 Nestle Sa Verfahren zur herstellung von milchpulver und konzentrierten milchprodukten
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
GB0208499D0 (en) * 2002-04-12 2002-05-22 Microscience Ltd Streptococcal genes
AU2003276828A1 (en) * 2002-05-10 2004-03-11 Children's Medical Center Corporation Minicell display and products therefrom
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
US20050282747A1 (en) * 2003-10-01 2005-12-22 The Research Foundation Of State University Of New York At Stony Brook Methods and compositions for wound healing
CA2511711A1 (en) * 2004-07-08 2006-01-08 Les Laboratoires Omega Ltee Liquid pharmaceutical formulations of octreotide, manufacturing process and container for the same
AU2005319578A1 (en) * 2004-11-24 2006-06-29 Neopro Labs, Llc Methods and compositions for treating conditions
US7550150B2 (en) * 2005-03-15 2009-06-23 Barros Research Institute Methods of treating or preventing a disease, disorder or condition associated with a viral infection
US20090011987A1 (en) * 2005-05-19 2009-01-08 Novo Nordisk A/S Use of Glp-2 for the Treatment of Ischemia-Reperfusion Injury
JP2009506076A (ja) * 2005-08-26 2009-02-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 三叉神経疼痛のための薬物送達のための治療手順
BRPI0616949A2 (pt) * 2005-10-07 2011-07-05 Waratah Pharmaceuticals Inc composição farmacêutica, uso de uma composição, e, kit
WO2007095737A1 (en) * 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
WO2007100335A1 (en) * 2006-03-03 2007-09-07 The Mclean Hospital Corporation Methods for the treatment of mood disorders
BRPI0708773B1 (pt) 2006-03-10 2021-10-19 Laboswiss Ag Método para solubilização, dispersão e estabilização de substâncias, produtos manufaturados de acordo com o método, bem como uso dos mesmos
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
DK2146733T3 (da) * 2007-03-14 2021-01-11 Arch Biosurgery Inc Treatment of leaky or damaged tight junctions and enhancing extracellular matrix

Also Published As

Publication number Publication date
US20100197608A1 (en) 2010-08-05
AU2008303950A1 (en) 2009-04-02
US20100184704A1 (en) 2010-07-22
EP2187923A2 (en) 2010-05-26
RU2010113966A (ru) 2011-10-20
CA2699107A1 (en) 2009-04-09
US20100210532A1 (en) 2010-08-19
KR20100061483A (ko) 2010-06-07
AU2008303811A1 (en) 2009-04-02
KR20100061678A (ko) 2010-06-08
CA2699049A1 (en) 2009-04-02
CA2699244A1 (en) 2009-04-02
WO2009040025A3 (en) 2009-05-22
WO2009033801A3 (en) 2009-09-03
JP2010538997A (ja) 2010-12-16
RU2010113981A (ru) 2011-10-20
WO2009049742A2 (en) 2009-04-23
JP2010539044A (ja) 2010-12-16
WO2009046857A1 (en) 2009-04-16
JP2010539034A (ja) 2010-12-16
WO2009040021A3 (en) 2009-06-25
AU2008303889A1 (en) 2009-04-02
WO2009033681A2 (en) 2009-03-19
EP2187906A2 (en) 2010-05-26
KR20100058553A (ko) 2010-06-03
KR20100058549A (ko) 2010-06-03
US20100190716A1 (en) 2010-07-29
US20100204130A1 (en) 2010-08-12
WO2009039988A3 (en) 2009-09-03
WO2009033781A2 (en) 2009-03-19
EP2187908A1 (en) 2010-05-26
WO2009040049A2 (en) 2009-04-02
WO2009039995A1 (en) 2009-04-02
KR20100057053A (ko) 2010-05-28
RU2010114047A (ru) 2011-10-20
WO2009039988A2 (en) 2009-04-02
WO2009043441A1 (en) 2009-04-09
AU2008297899A1 (en) 2009-03-19
WO2009033781A3 (en) 2009-10-29
WO2009033803A2 (en) 2009-03-19
RU2010114000A (ru) 2011-10-20
WO2009040071A3 (en) 2009-12-17
AU2008303957A1 (en) 2009-04-02
RU2010113995A (ru) 2011-10-20
AU2008306264A1 (en) 2009-04-09
RU2010114027A (ru) 2011-10-20
KR20100057058A (ko) 2010-05-28
AU2008314244A1 (en) 2009-04-23
EP2187917A2 (en) 2010-05-26
CA2699177A1 (en) 2009-04-02
EP2205262A2 (en) 2010-07-14
CA2699054A1 (en) 2009-04-02
RU2010114025A (ru) 2011-10-20
CA2699075A1 (en) 2009-04-23
WO2009033659A1 (en) 2009-03-19
WO2009039974A2 (en) 2009-04-02
JP2010539023A (ja) 2010-12-16
EP2185180A1 (en) 2010-05-19
AU2008303951A1 (en) 2009-04-02
EP2187925A1 (en) 2010-05-26
WO2009039989A1 (en) 2009-04-02
CA2698978A1 (en) 2009-03-19
WO2009040021A2 (en) 2009-04-02
WO2009033730A3 (en) 2009-10-01
WO2009043459A1 (en) 2009-04-09
JP2010539019A (ja) 2010-12-16
JP2010539040A (ja) 2010-12-16
WO2009040049A3 (en) 2009-09-24
WO2009040025A2 (en) 2009-04-02
WO2009033803A3 (en) 2009-05-14
WO2009033681A3 (en) 2009-09-24
CA2698775A1 (en) 2009-04-02
WO2009033765A2 (en) 2009-03-19
US20100190711A1 (en) 2010-07-29
JP2010539004A (ja) 2010-12-16
WO2009040071A2 (en) 2009-04-02
US20100197601A1 (en) 2010-08-05
WO2009033725A1 (en) 2009-03-19
JP5385282B2 (ja) 2014-01-08
KR20100059855A (ko) 2010-06-04
WO2009039974A3 (en) 2009-07-16
WO2009033730A2 (en) 2009-03-19
KR20100056511A (ko) 2010-05-27
WO2009033765A3 (en) 2009-08-20
US20100204115A1 (en) 2010-08-12
EP2187952A1 (en) 2010-05-26
WO2009049742A3 (en) 2009-09-03
JP2010538998A (ja) 2010-12-16
WO2009033801A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
RU2010113977A (ru) Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
RU2010113975A (ru) (D-Leu)-ГИСТРЕЛИН В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010114061A (ru) ПРИМЕНЕНИЕ ПЕПТИДА His-Ser-Leu-Gly-Lys-Trp-Leu-His-Pro-Asp-Lys-Phe ИНДИВИДУАЛЬНО ИЛИ В КОМБИНАЦИИ С ПЕПТИДОМ Gly-Arg-Gly-Asp-Asn-Pro-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010114009A (ru) Применение rgdspasskp и необязательно ангиотензина ii в качестве терапевтических средств при лечении, например, инфекций s. pneumoniae
RU2010114028A (ru) Применение ангиотензина ii в качестве терапевтического средства, например, при инфекции s. pneumoniae
RU2010113969A (ru) Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств
RU2010114023A (ru) ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010113985A (ru) Применение уродилатина в качестве терапевтического средства
RU2010113999A (ru) Применение секретина и необязательно уродилатина в качестве терапевтических средств
RU2010114010A (ru) Применение октреотида в качестве терапевтического средства
RU2010114018A (ru) Применение пептид тимозина бета 4 индивидуально или в сочетании с цекропином а в качестве терапевтического средства
RU2010114044A (ru) Применение белка полосы 3 (824-829) и/или фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa
RU2010114045A (ru) Применение пептида sfllr-oh и мурамилдипептида в качестве терапевтических средств
RU2010114049A (ru) Cgrp в качестве терапевтического средства
RU2010114051A (ru) Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств
RU2010114030A (ru) Применение пептида в качестве терапевтического средства
RU2010114050A (ru) Применение пептида рецептора il-1 индивидуально или в комбинации с октадециловым эфиром d-ala-gln в качестве терапевтического средства
RU2010114003A (ru) Применение пептида фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
RU2010114062A (ru) ПРИМЕНЕНИЕ ПЕПТИДА Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010114005A (ru) Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства
RU2010114037A (ru) Применение белка полосы 3 и расар-27 в качестве терапевтического средства
RU2010114060A (ru) Применение пептида в качестве терапевтического средства

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110912